Antibody Production Market was valued at US$9.93 billion in the year 2018 and is expected to reach US$23.22 billion by 2026, at a CAGR of 12.29%.
Antibodies are protein molecules resembling the alphabet ‘Y’. They are innately produced by plasma cells as a primary response and also produced by B cells. They are a part of the immune system that protects against toxins, antigens, and pathogens such as bacteria and viruses. When an antigen or an organism enters the body, the macrophages present them to B cells. The B cells codes for a new antibody containing an antigen-binding site that is specific to the epitope of the antigen. The antibodies are then released to the bloodstream and B cells produce the same type of antibodies if they encounter with the same antigen once again.
The spotlight on antibodies arose due to its high specificity towards the targeted cells while sparing the normal cells. The antibodies can be custom-made against a particular epitope through hybridoma technology. The antibodies which target one epitope are monoclonal antibodies (mAbs) whereas antibodies targeting multiple epitopes are denoted as polyclonal antibodies. The ability to produce antibodies by connecting to specific antigens is used in manufacturing probes that have the capability of identifying specific molecules and can be used across a spectrum of research and diagnostic purposes.
With more inclination towards targeted antibody therapy, and with biotechnology and biopharmaceutical companies focusing more on antibody production for specific requirements, the market is set to grow at a CAGR of 12.29% during the forecast period.
Rising geriatric population around the world, increase in the prevalence of infectious and disorders such as cancer, rheumatoid arthritis, and other chronic diseases, more and more interest towards targeted therapy are driving the antibody production market. Also, there is a steep surge in the antibody production due to an increase of biotechnology and biopharmaceutical organizations investing more funds in research and development owing to develop advanced biologics and therapeutics with a principal focus on monoclonal antibodies. However, an increase in the number of local players, cost of the therapy and failure during approvals are the factors which may likely hamper the market growth.
More than 650 companies are present in the field of antibody production and more and more therapeutic uses are being discovered. The long-term strategy for market sustenance and attaining leadership in the sector will happen through partnerships and collaborations. Further, patent expiry on several blockbuster mAbs is yet another factor that will support the antibody production market. For example, Herceptin patent expired in Europe in the year 2014 and its US patent expired in June. Following the expiration of Samsung epis patent, Mylan and Biocon have already obtained FDA approval for Herceptin Biosimilar. Companies such as Amgen, Allergan, Pfizer, etc., are also keen on launching their biosimilar depending upon the competition, pricing of the competitors, etc.
The antibody production market is categorized based on the type of antibodies, production process, end-use, and regions.
The monoclonal antibody (mAbs) segment engrossed maximum revenue when compared to the polyclonal antibody segment, in the year 2016-17 and is set to capture the market in the forecast period. This is due to the upsurge of investments in mAb research and more interests towards targeted therapeutic approaches, the launch of new products, etc. However, the polyclonal antibody segment will also contribute owing to its increasing popularity, production cost, etc. reaching over US$ 1 billion by 2024. The antibodies used for research purposes will contribute more towards the market growth, than the contribution of polyclonal antibodies.
Generally, bioreactors are utilized for large-scale production of antibodies. Following which they are clarified using the downstream methodology which involves sophisticated, precise and effective procedure including filtration, chromatography, resins, etc. The downstream processing segment chiefly contributes to the antibody production market.
Owing to the production of antibodies with superior product quality and production of novel therapeutic antibodies, the filtration and upstream processing segment will play a crucial role in the forthcoming years and will significantly contribute to the market growth.
The pharmaceutical and the biotechnology companies are said to dominate the overall market share with maximum revenue generation in the years 2016 to 2018. With more new market entrants, products in the pipeline, major players planning to expand their product portfolio, more investments in therapeutic development, the pharma and biotech companies will lead the market growth by a significant margin.
Especially in the continent of North America, where the conditions for R&D are very favorable and increasing advancement for treating chronic disorders promptly puts it ahead in the revenue generation over other regions. However, awareness of treatment for chronic disorders in the Asia Pacific regions will slowly grow towards the end of 2021, especially in countries such as India and China, where the scope of investment for developing therapeutics is huge due to its diversity in the genomic pool, lack of stringent regulations, continual improvement in healthcare infrastructure, etc.
Companies such as GE Healthcare, Thermo Fisher Scientific, Inc., Pall Corporation, INTEGRA Biosciences AG, Eppendorf AG, Danaher Corporation, Abcam plc, etc. all focus on both upstream and downstream segments.
The Antibody Production Market Outlook 2019-2026, from Optima Insights, will offer a thorough insight on the market growth till the forecast year 2026 based on the market segmentation (Type, Process, End-Use, and Region). The report also comprises comprehensive profiling of companies involved in antibody production, product information and pipeline information.
The Report Provides Key Insights on
- History of the Antibody Production Market, 2015 to 2017
- Forecast of the Antibody Production Market Growth till the year 2026
- The key market drivers, restraints, challenges, future opportunities and the market dynamics driving the Antibody Production Market
- Analysis of potential growth segments which will drive the market
- Landscape analysis of the major companies, and new market entrants and companies which possess disruptive technologies which can change the trend of the entire market
- Key market approaches adopted by the organizations and in-depth intelligence of potential strategies which could alter the market dynamics
Antibody Production Market Based on Process (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)
- Upstream Processing
- Consumables
- Reagents and Buffers
- Media
- Bioreactors
- Single-Use Bioreactors (SUBS)
- Large-Scale Bioreactors
- Filtration
- Filtration Systems
- Consumables & Accessories
- Purification Process
- Chromatography Resins
- Chromatography Systems
Antibody Production Market Based on Type (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)
- Monoclonal Antibody
- Humanized
- Chimeric
- Murine
- Polyclonal Antibody
Antibody Production Market Based on End-User (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)
- Research Laboratories
- Pharmaceutical Companies
- Biotechnology Companies
Antibody Production Market Based on Geographic Region (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)
- North America
- Europe
- APAC
- LAMEA
Antibody Production Market Competitive Analysis (Company Overview, SWOT Matrix, Financial, Product Overview, and Market Strategies)
- Thermo Fisher Scientific, Inc.
- Sartorius AG
- Merck KGaA
- Pall Corporation
- Eppendorf AG
- Danaher Corporation
- Miltenyi Biotec
- Bio-Rad Laboratories Inc
About Us
Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to make better business decisions towards attaining market leadership.
Contact
Optima Insights
Mr Chucks G
+91 966 6620 365 (Asia) | +1 424 2554 365 (US)
Email:Sales@optimainsights.org
https://www.optimainsights.org
